Latest News - Psoriasis

Friday, August 04, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Pfizer

FDA Advisory Arm Backs XELJANZ for PsA

The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active pso…

Read the full story

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Atopic Derm, Atopic Dermatitis , Eczema, Psoriasis, Valeant NJ

Valeant’s Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AAD

It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch …

Read the full story

Thursday, July 27, 2017 | PracticalDermatology.com, Product Launches and Updates, AbbVie, Boehringer Ingelheim

Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humira

The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 4…

Read the full story

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Valeant NJ

Valeant Launches Siliq Injection for Psoriasis

 Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York fro…

Read the full story

Thursday, July 20, 2017 | PracticalDermatology.com, Leo

LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasis

The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the Eur…

Read the full story

Thursday, July 13, 2017 | FDA Approval/Clearance, PracticalDermatology.com

FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasis

The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the fir…

Read the full story

Thursday, July 13, 2017 | FDA Approval/Clearance, PracticalDermatology.com, PracticalDermatology.com

FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Home

The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical de…

Read the full story

Monday, July 10, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Celgene

Dr. Jacqualyn Fouse Named Executive Chairman of Dermavant

Dr. Jacqualyn "Jackie" Fouse is the new Executive Chairman of Dermavant Sciences. Part of the Roivant Sciences family of companies, Dermavant Sciences is developing and, upon regulatory a…

Read the full story

Wednesday, July 05, 2017 | PracticalDermatology.com, Sun Pharmaceutical Industries Ltd

Samsung Biologics to Manufacture Sun Pharma’s Tildrakizumab for Psoriasis

Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is …

Read the full story

Thursday, June 15, 2017 | Phase 3/4 Trials, PracticalDermatology.com

PsA Patients Failing Anti-TNF Drugs May Do Well on Taltz

New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant o…

Read the full story

Wednesday, June 07, 2017 | Phase 3/4 Trials, PracticalDermatology.com, Sun Pharmaceutical Industries Ltd

Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studies

Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who rece…

Read the full story

Tuesday, June 06, 2017 | PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates

FDA Clears Clarify Medical Core Technology for At-home UVB Phototherapy

The US Food and Drug Administration has cleared the Clarify Medical Phototherapy System for marketing, and the new smart, at-home UVB phototherapy system will be available to patients with chronic ski…

Read the full story

Tuesday, June 06, 2017 | PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Game Change: New Handheld Tissue Scanner Can See Below Surface of Skin in Psoriasis

A new handheld tissue scanner allows dermatologists to look below the surface of skin in psoriasis patients and can provide clinically relevant information, such as the structure of skin layers a…

Read the full story

Wednesday, May 24, 2017 | PracticalDermatology.com, Product Launches and Updates, Sun Pharmaceutical Industries Ltd

Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumab

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the tre…

Read the full story

Wednesday, May 24, 2017 | PracticalDermatology.com, Research and Publications, 23andMe , Psoriasis

Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clues

A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how -- and why -- psoriasis develops. University of Michigan researchers, wor…

Read the full story
Load More